Core Insights - Thermo Fisher Scientific Inc. is a leading life sciences and technology company with a market cap of approximately $193.7 billion, indicating its significant size and influence in the healthcare and diagnostics sectors [1][2] Company Overview - The company develops and supplies scientific instruments, laboratory equipment, specialty diagnostics, reagents, and biopharmaceutical services for research, healthcare, and industrial markets globally [1] - Thermo Fisher has established a dominant presence in research, diagnostics, laboratory equipment, and biopharma services, supported by substantial investments in R&D and strong integrated systems [2] Stock Performance - The stock is currently down 19.9% from its 52-week high of $643.99, reached on January 22, and has decreased 12% over the past three months, underperforming compared to the iShares US Medical Devices ETF, which declined 7.5% in the same period [3] - Year-to-date, the stock is down 11% and has fallen 3.7% over the past 52 weeks, while the IHI ETF has seen a decline of 4.1% in 2026 and 6.8% over the past year [4] Financial Performance - In Q4 2025, the company reported revenue of approximately $12.2 billion, reflecting a 7% year-over-year growth, and adjusted EPS of $6.57, an 8% increase, surpassing Wall Street estimates [6] - Full-year revenue for 2025 grew by 4% to around $44.6 billion, indicating solid earnings despite cautious guidance from the company [6]

Company Overview - Revvity, Inc. is headquartered in Waltham, MA, and provides scientific instruments, consumables, and services to various markets including pharmaceutical, biomedical, environmental testing, chemical, and general industrial sectors. The company was previously known as PerkinElmer until March 2023 [11]. Recent Developments - In March 2023, Revvity completed the sale of its Applied, Food and Enterprise Services (AES) businesses to New Mountain Capital for up to $2.45 billion. Following this divestiture, the company changed its name to Revvity effective April 26, 2023, and its ticker symbol changed from PKI to RVTY on May 16, 2023 [11]. Stock Performance - Revvity (RVTY) currently holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of B. The stock has a Momentum Style Score of A, and shares have increased by 4.9% over the past four weeks [12]. - Two analysts have revised their earnings estimates upwards for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.02 to $5.33 per share. Revvity has an average earnings surprise of +4.1% [12]. Investment Consideration - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, Revvity is recommended to be on investors' short list for potential investment opportunities [13].

分组1 - Revvity (RVTY) reported quarterly earnings of $1.7 per share, exceeding the Zacks Consensus Estimate of $1.63 per share, and up from $1.42 per share a year ago, representing an earnings surprise of +4.29% [1] - The company posted revenues of $772.06 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.02%, and an increase from $729.37 million year-over-year [2] - Revvity has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained approximately 12.5% since the beginning of the year, compared to the S&P 500's gain of 1.4% [3] - The current consensus EPS estimate for the upcoming quarter is $1.11 on revenues of $679.95 million, and for the current fiscal year, it is $5.32 on revenues of $2.94 billion [7] - The Zacks Industry Rank indicates that the Medical Services sector is currently in the bottom 27% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Viewpoint - Thermo Fisher Scientific Inc. is poised to report strong quarterly earnings, with anticipated growth in both earnings per share and revenue, reflecting its robust market position and demand for its products [1][2]. Financial Performance - Analysts expect Thermo Fisher to report an earnings per share (EPS) of $6.43, representing a 5.4% increase from the same period last year [2][6]. - Projected revenue is approximately $11.94 billion, indicating a 4.8% year-over-year growth [2][6]. Market Reactions - There has been a slight downward revision of 0.1% in the consensus EPS estimate over the past month, which may influence short-term stock price movements [3]. Valuation Metrics - The company has a price-to-earnings (P/E) ratio of approximately 35.90, indicating strong investor confidence in future growth prospects [4][6]. - The price-to-sales (P/S) ratio stands at about 5.36, reflecting the value placed on each dollar of sales [4][6]. - The enterprise value to sales ratio is around 6.13, and the enterprise value to operating cash flow ratio is approximately 35.04, highlighting the company's valuation in relation to its sales and cash flow [5]. Financial Health - Thermo Fisher maintains a debt-to-equity ratio of approximately 0.70, indicating a moderate level of debt compared to its equity [5]. - A current ratio of about 1.50 suggests good liquidity to cover short-term liabilities [5].

Core Insights - Financial giants are showing a bearish sentiment towards Thermo Fisher Scientific, with 55% of traders exhibiting bearish tendencies and only 22% being bullish [1] - Significant investors are targeting a price range of $390.0 to $560.0 for Thermo Fisher Scientific over the past three months [2] Options Trading Activity - The analysis of options trading revealed 9 unusual trades, including 2 puts valued at $176,400 and 7 calls valued at $558,411 [1] - The largest options trades include bearish calls and puts, with notable trades at strike prices of $390.00 and $560.00 [7] Volume and Open Interest - Monitoring volume and open interest provides insights into the liquidity and interest in Thermo Fisher Scientific's options, particularly within the $390.0 to $560.0 strike price range over the last 30 days [3][4] Company Overview - Thermo Fisher Scientific operates in four segments: analytical technologies (17% of sales), specialty diagnostic products (11%), life science solutions (23%), and lab products and services [8] Analyst Ratings and Price Targets - Recent expert ratings suggest an average target price of $687.0, with various analysts adjusting their ratings and price targets, including Goldman Sachs lowering to $685 and Citigroup upgrading to $660 [9][10] Current Market Position - The stock is currently trading at $577.22, reflecting a 0.59% increase, with a volume of 699,377 [12]

Core Insights - The BBH Select Series - Mid Cap Fund experienced a total return decrease of -0.9% in Q3 2025, underperforming the Russell Midcap Index which returned 5.3% [1] - Year-to-date, the fund's total return is -1.8%, compared to the Index's 10.4% [1] - The third quarter saw a continuation of the low-quality rally that began late last year, gaining momentum throughout 2025 [1] Company Highlights - Bruker Corporation (NASDAQ:BRKR) was highlighted in the fund's Q3 2025 investor letter, focusing on its development and manufacturing of scientific instruments and analytical solutions [2] - Bruker Corporation's one-month return was 12.28%, but it has lost 19.82% of its value over the last 52 weeks [2] - As of December 10, 2025, Bruker Corporation's stock closed at $46.92 per share, with a market capitalization of $7.129 billion [2] Performance Detractors - The largest detractors to the fund's performance in Q3 2025 included Shift4 Payments Inc., Globant S.A., and Bruker Corporation [3] - The fund exited positions in both Globant and Bruker during the quarter due to sustained underperformance and to opportunistically harvest tax losses [3] - Bruker Corporation was notably impacted by tariffs and cuts in life science and academic funding, with any potential re-entry into the stock contingent on performance stabilization [3]

Core Insights - The London Company reported a 6.3% return (6.2% net) for its Large Cap Strategy in Q3 2025, underperforming the Russell 1000 Index which gained 8.0% during the same period [1] - The overall economic momentum remained strong despite mixed economic data in Q3 2025, driven by a Fed rate cut, solid corporate earnings, and enthusiasm around AI [1] Company-Specific Insights - Bruker Corporation (NASDAQ:BRKR) was highlighted in the investor letter, with a one-month return of 6.17% but a significant 34.78% decline over the past 52 weeks, closing at $38.71 per share with a market capitalization of $5.873 billion on November 3, 2025 [2] - The London Company decided to exit its position in Bruker Corporation due to significant underperformance since purchase in 2024, citing weak pharma spending, potential cuts to NIH and academic funding, and tariff concerns as headwinds [3] - Bruker Corporation is not among the 30 most popular stocks among hedge funds, with 42 hedge fund portfolios holding the stock at the end of Q2 2025, an increase from 40 in the previous quarter [4]

Core Insights - Agilent Technologies' international operations are crucial for understanding its financial resilience and growth potential [1][2] - The company's reliance on foreign markets is essential for consistent earnings and navigating different economic cycles [2][3] Revenue Performance - Total revenue for the recent quarter reached $1.74 billion, reflecting a 10.1% increase from the prior-year quarter [4] - Asia Pacific contributed $563 million, accounting for 32.4% of total revenue, but showed a decline of -1.9% compared to analyst expectations [5] - Europe generated $492 million, representing 28.3% of total revenue, with a positive surprise of +16.47% compared to projections [6] Future Revenue Expectations - Analysts predict total revenue of $1.83 billion for the current fiscal quarter, indicating a 7.8% increase year-over-year [7] - For the full year, total revenue is expected to reach $6.86 billion, up 5.4% from the previous year, with Asia Pacific and Europe projected to contribute $2.29 billion and $1.77 billion, respectively [8] Market Dynamics - The company's international revenue trends present both opportunities and challenges, necessitating close monitoring for future projections [9] - Global interconnections and geopolitical issues are increasingly influencing earnings predictions for companies with overseas operations [10] Stock Performance - Agilent's stock has increased by 10.7% over the past month, outperforming the S&P 500's 1.6% increase [13] - Over the past three months, the company's shares rose by 8.5%, while the S&P 500 increased by 9.7% [13]

Company Performance - Rockwell Medical reported a quarterly loss of $0.05 per share, aligning with the Zacks Consensus Estimate, compared to earnings of $0.01 per share a year ago [1] - The company posted revenues of $16.07 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.27%, but down from $25.83 million year-over-year [2] - Over the last four quarters, Rockwell Medical has surpassed consensus revenue estimates four times, but has only done so for EPS estimates once [2] Stock Movement and Outlook - Rockwell Medical shares have declined approximately 48.8% since the beginning of the year, contrasting with a 10% gain in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.05 on revenues of $16.67 million, and -$0.18 on revenues of $69.62 million for the current fiscal year [7] Industry Context - The Medical - Products industry, to which Rockwell Medical belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Rockwell Medical's stock performance [5][6]

Company Overview - Revvity (RVTY) is anticipated to report a year-over-year decline in earnings of 6.6%, with expected earnings of $1.14 per share, while revenues are projected to increase by 2.8% to $711.27 million for the quarter ended June 2025 [3][12]. Earnings Expectations - The earnings report is scheduled for release on July 28, and the stock may experience upward movement if the reported figures exceed expectations; conversely, a miss could lead to a decline in stock price [2][12]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - Revvity has an Earnings ESP of +0.88%, suggesting a higher Most Accurate Estimate compared to the Zacks Consensus Estimate, indicating a bullish outlook from analysts [12]. - The company has a Zacks Rank of 3, which, when combined with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - Revvity has consistently beaten consensus EPS estimates in the past four quarters, with a notable surprise of +5.21% in the last reported quarter [13][14]. Industry Context - In comparison, Labcorp Holdings (LH), another player in the medical services industry, is expected to report earnings of $4.14 per share, reflecting a year-over-year increase of 5.1%, with revenues projected at $3.49 billion, up 8.3% [18]. - Labcorp's consensus EPS estimate has been revised down by 0.1% over the last 30 days, resulting in an Earnings ESP of -0.26%, making it challenging to predict a beat against the consensus EPS estimate [19].